A Randomized, Double-Blind, Placebo-Controlled, 4-week Trial of IMO-3100 in Patients With Moderate to Severe Plaque Psoriasis

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, 4-week Trial of IMO-3100 in Patients With Moderate to Severe Plaque Psoriasis

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Oct 2013

At a glance

  • Drugs IMO 3100 (Primary)
  • Indications Plaque psoriasis
  • Focus Therapeutic Use
  • Sponsors Idera Pharmaceuticals
  • Most Recent Events

    • 28 Oct 2013 Results presented at the 77th American College of Rheumatology and the 48th Annual Meeting of the Association of Rheumatology and Health Professionals.
    • 13 May 2013 Results presented at the International Investigative Dermatology meeting, according to an Idera media release.
    • 19 Dec 2012 Top-line results published in an Idera Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top